FibroGen, Inc (FGEN)
FibroGen, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for unmet medical needs. The company specializes in innovative treatments for fibrotic diseases, anemia associated with chronic kidney disease, and certain cancers. Founded in 2001 and headquartered in San Francisco, FibroGen leverages its expertise in fibrosis and erythropoiesis to advance its pipeline of potential therapies.
Company News
FibroGen received approval from the China State Administration for Market Regulation to sell FibroGen International (Hong Kong) Ltd. to AstraZeneca. The transaction is expected to close in Q3 2025 with a total consideration of approximately $210 million.
AstraZeneca has acquired FibroGen's Chinese subsidiary for $160 million, strengthening its position in the Chinese market and enabling FibroGen to focus on its pipeline development in the US.
Zoetis (ZTS) delivered earnings and revenue surprises of 2.99% and 2.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
HP, Box, VinFast Auto and Ambarella are among the stocks on the move.